Syngene International Ltd

Q1 FY26Healthcare Services

Syngene International Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹407

Market cap₹16.4K Cr

P/E55.5

Updated23 Aug 2026

Read4 min read

The short version

Syngene expects continued revenue growth driven by strong momentum in Research Services, accounting for 67% of sales in Q1 FY '26. Syngene expects underlying revenue growth in early teens for FY '26 after adjusting for client inventory rebalancing in biologics commercial manufacturing.

From Syngene International Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Syngene expects continued revenue growth driven by strong momentum in Research Services, accounting for 67% of sales in Q1 FY '26.
Early signs point to healthy pipeline development and conversion of pilot projects into full contracts.
The biologics business, including new Unit 3 and Bayview facilities, is expected to ramp up over 3 to 5 years, with efforts to accelerate this timeline where possible.
Underlying business growth is expected in the early teens annually, but overall reported revenue growth is guided in mid-single digits due to client inventory adjustments in biologics manufacturing.
Capacity utilization in small molecule manufacturing (Mangalore) is expected to increase over the year.
Syngene aims to leverage new capacities and geographic expansion (US Bayview facility) to capture a larger market share in a sizable global CRO/CDMO market.
Continued investments in capabilities and technology will underpin medium-term growth, with growth opportunities from multinational and midsize biopharma clients.

Profitability & Margins

Syngene expects underlying revenue growth in early teens for FY '26 after adjusting for client inventory rebalancing in biologics commercial manufacturing.
Reported revenue growth for FY '26 is guided at mid-single digits.
EBITDA margins for FY '26 are expected in the mid-20% range, despite margin pressure from increased depreciation due to new facilities coming online (Unit 3 and Bayview).
Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year.
PAT before exceptional items in Q1 FY '26 increased 59% YoY, partly due to a one-time tax benefit.
The ramp-up of biologics capacity (Bayview and Unit 3) is expected over 3-5 years, with efforts ongoing to accelerate this timeline.
The company maintains a confident outlook but will monitor macroeconomic factors and market uncertainties before making guidance adjustments.

See what Syngene International Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Syngene incurred around $8 million capex during the quarter across businesses.
Approximately 30% of capex invested in Research Services focusing on capability builds, including peptides, ADCs, and dedicated centres.
Nearly 55% of capex directed towards CDMO business for new formulation facilities in small molecules and modifications at Unit 3 biologics facility.
Remaining capex spent on digitization, automation, and common infrastructure.
Plans to continue strategic investments and capability builds to be future-ready.
Unit 3 and Bayview biologics facilities are becoming operational in FY '26, with ramp-up expected over 3 to 5 years.
Bayview facility offers versatility and US market presence; operationalization expected in the second half of the year.
Investments expected to drive medium-term growth as utilization improves and strengthen Syngene's biologics CDMO market position.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹981 Cr

Rev 1Mar 1

2CHANDAN₹518 Cr

Rev 1Mar 3

3₹66.5K Cr

Rev 2Mar 1

4₹654 Cr

Rev 2Mar 2

5₹1.3L Cr

Rev 2Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
Syngene maintains a strong balance sheet with net cash of INR1,053 crores (~$123 million) as of June 2025 after capex spending.
Reported interest expenses declined by 1% due to reduced borrowings compared to the previous year.
The company continues to make strategic investments and capex, funded from existing resources.
No comments indicate intentions for raising new debt or equity at this time; management emphasizes careful planning of investments and maintaining financial stability.

See what Syngene International Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not provide explicit quantitative details on the current or expected order book/pending orders.
There is mention of a healthy pipeline of pilot projects in the Research Services business, including strong interest and ongoing conversion of pilot CRO projects into full-fledged contracts.
Bayview facility in the US is seeing healthy interest from potential customers.
The Mangalore small molecule plant has an active pipeline across the value chain, including starting materials, intermediates, and APIs, though no specific project count is given.
The complex nature of client project structures (with some like Emergent having potential rights of first refusal) indicates ongoing client engagements but without disclosing specific order volumes.
Overall, the company expresses optimism about pipeline growth and business conversion but refrains from sharing concrete order book numbers currently.

Syngene International Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹1.0K Cr, net profit ₹148 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Syngene Intl.'s management said in earlier quarters

Others in Healthcare Services this season

Aster DM Quality (Q1 FY26)
Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…
Dr Agarwal's Hea (Q1 FY26)
70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…
Yatharth Hospit. (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…
Rainbow Child. (Q1 FY26)
Around 50% of the total planned bed additions will be on an asset-light model. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q1 FY26 earnings…

Compare:vs Apollo Hospitals vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Syngene International Ltd Q1 FY26 results?

What is Syngene International Ltd share price analysis?

Syngene International Ltd currently shows a neutral. The stock trades at a P/E of 55.5 with a market cap of ₹16,427 Cr. Investors should review the full earnings analysis for detailed insights.

Is Syngene International Ltd planning capital expenditure?

Syngene incurred around $8 million capex during the quarter across businesses.

Keep Syngene International Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.